Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic landscape of superficial malignant peripheral nerve sheath tumor.
McAfee JL, Alban TJ, Makarov V, Rupani A, Parthasarathy PB, Tu Z, Ronen S, Billings SD, Diaz CM, Chan TA, Ko JS. McAfee JL, et al. Among authors: rupani a. Lab Invest. 2024 Nov 10:102183. doi: 10.1016/j.labinv.2024.102183. Online ahead of print. Lab Invest. 2024. PMID: 39532239
LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses.
Ta HM, Roy D, Zhang K, Alban T, Juric I, Dong J, Parthasarathy PB, Patnaik S, Delaney E, Gilmour C, Zakeri A, Shukla N, Rupani A, Phoon YP, Liu C, Avril S, Gastman B, Chan T, Wang LL. Ta HM, et al. Among authors: rupani a. Sci Immunol. 2024 May 17;9(95):eadi7418. doi: 10.1126/sciimmunol.adi7418. Epub 2024 May 17. Sci Immunol. 2024. PMID: 38758807 Free PMC article.
VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms.
Zhang K, Zakeri A, Alban T, Dong J, Ta HM, Zalavadia AH, Branicky A, Zhao H, Juric I, Husich H, Parthasarathy PB, Rupani A, Drazba JA, Chakraborty AA, Ching-Cheng Huang S, Chan T, Avril S, Wang LL. Zhang K, et al. Among authors: rupani a. Cell Rep. 2024 Jan 23;43(1):113661. doi: 10.1016/j.celrep.2023.113661. Epub 2024 Jan 3. Cell Rep. 2024. PMID: 38175754 Free PMC article.
Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.
Wilkerson AD, Parthasarathy PB, Stabellini N, Mitchell C, Pavicic PG Jr, Fu P, Rupani A, Husic H, Rayman PA, Swaidani S, Abraham J, Budd GT, Moore H, Al-Hilli Z, Ko JS, Baar J, Chan TA, Alban T, Diaz-Montero CM, Montero AJ. Wilkerson AD, et al. Among authors: rupani a. Clin Cancer Res. 2024 Jan 5;30(1):82-93. doi: 10.1158/1078-0432.CCR-23-1349. Clin Cancer Res. 2024. PMID: 37882661 Free PMC article. Clinical Trial.
Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression.
Pavicic PG Jr, Rayman PA, Swaidani S, Rupani A, Makarov V, Tannenbaum CS, Edwards RP, Vlad AM, Diaz-Montero CM, Mahdi H. Pavicic PG Jr, et al. Among authors: rupani a. Oncoimmunology. 2023 Apr 10;12(1):2198185. doi: 10.1080/2162402X.2023.2198185. eCollection 2023. Oncoimmunology. 2023. PMID: 37066116 Free PMC article.
35 results